Review Article

RNA and Oxidative Stress in Alzheimer’s Disease: Focus on microRNAs

Akihiko Nunomura1 and George Perry2

1Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
2Department of Biology and Neurosciences Institute, University of Texas at San Antonio, San Antonio, USA

Correspondence should be addressed to Akihiko Nunomura; anunomura@jikei.ac.jp

Received 23 July 2020; Revised 21 October 2020; Accepted 29 October 2020; Published 30 November 2020

Copyright © 2020 Akihiko Nunomura and George Perry. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative stress (OS) is one of the major pathomechanisms of Alzheimer’s disease (AD), which is closely associated with other key events in neurodegeneration such as mitochondrial dysfunction, inflammation, metal dysregulation, and protein misfolding. Oxidized RNAs are identified in brains of AD patients at the prodromal stage. Indeed, oxidized mRNA, rRNA, and tRNA lead to retarded or aberrant protein synthesis. OS interferes with not only these translational machineries but also regulatory mechanisms of noncoding RNAs, especially microRNAs (miRNAs). MiRNAs can be oxidized, which causes misrecognizing target mRNAs. Moreover, OS affects the expression of multiple miRNAs, and conversely, miRNAs regulate many genes involved in the OS response. Intriguingly, several miRNAs embedded in upstream regulators or downstream targets of OS are involved also in neurodegenerative pathways in AD. Specifically, seven upregulated miRNAs (miR-125b, miR-146a, miR-200c, miR-26b, miR-30e, miR-34a, miR-34c) and three downregulated miRNAs (miR-107, miR-210, miR-485), all of which are associated with OS, are found in vulnerable brain regions of AD at the prodromal stage. Growing evidence suggests that altered miRNAs may serve as targets for developing diagnostic or therapeutic tools for early-stage AD. Focusing on a neuroprotective transcriptional repressor, REST, and the concept of hormesis that are relevant to the OS response may provide clues to help us understand the role of the miRNA system in cellular and organismal adaptive mechanisms to OS.

1. Introduction

The process of neurodegeneration in Alzheimer’s disease (AD), the most common cause of dementia and a major concern in the aging population across the world, is a dynamic, multifaceted biochemical phenomenon and is essentially lifelong. Oxidative stress (OS) is considered as one of the major underlying mechanisms of AD and related neurodegenerative disorders. Indeed, oxidative damage is closely associated with other pathological key events in neurodegeneration such as mitochondrial dysfunction, inflammation, impaired calcium homeostasis, metal dysregulation, protein misfolding, and impaired autophagy [1, 2]. Several kinds of research materials, i.e., postmortem brain samples and biological fluid from the patients with prodromal-stage of AD, genetically modified animal models of AD, as well as disease models using induced pluripotent stem cells (iPSCs), all provide consistent evidence that OS is a significant early event in the pathological cascade of AD [3–7]. Strikingly, both transgenic animals and iPSC models of AD indicate that a prominent elevation of OS markers occurs simultaneously with or even prior to the initial AD-related amyloid-β (Aβ) and tau pathology [5–7].

In contrast to DNA, oxidative damage to RNA has not been a major focus of research until recently, which is presumably due to the assumed transient nature of RNA. However, RNAs including messenger RNA (mRNA) can persist for several hours to days in certain tissues, suggesting that damaged mRNAs are detrimental to the cell if not corrected [8–10]. Increased levels of an oxidized base and an oxidized nucleoside of RNA, 8-oxo-guanine (8-oxoGua), and 8-oxoguanosine (8-oxoGuo) were demonstrated in the vulnerable neuronal populations in postmortem brains of patients with preclinical AD and mild cognitive impairment (MCI) stage.
of AD [11–13] as well as in brains of gene-driven animal models of AD at an early stage of degeneration [14, 15]. The 8-oxoGua formation in neuronal RNA is not merely an epiphenomenon but a potentially lethal insult for cells because a recent experimental study elucidates the distinct pathway between heavily oxidized mRNA and apoptotic cell death [16].

Oxidative RNA damage affects not only mRNAs but also noncoding RNA species. Among them, microRNAs (miR-NAs), which interfere with the translation of target mRNAs, are of particular interest since their dysregulation has been implicated in neurodegenerative disorders like AD [17, 18]. Indeed, a cellular experiment has demonstrated that miRNAs can be directly oxidized and subsequently misrecognize mRNAs that are not their native targets [19]. Given the notion that noncoding RNAs are expected to contribute towards the biological complexity of the mammalian brain and cognitive evolution [20, 21], oxidative damage to non-coding RNAs and consequent dysregulation of the gene expression might be involved in the central pathophysiology of diverse neuropsychiatric disorders affecting higher brain functions [22, 23]. Besides direct oxidation of miRNAs, there is growing knowledge that OS affects expression levels of multiple miRNAs; conversely, miRNAs regulate lots of genes involved in the OS response [24, 25]. Intriguingly, several miRNAs embedded in oxidative stress regulation are involved also in several known pathways of neurodegeneration in AD, Parkinson’s disease (PD), amyotrophic lateral sclerosis, and Huntington’s disease [26, 27]. Further investigations towards elucidating the possible involvement of the oxidatively modified miRNAs and oxidatively altered miRNAs networks in the neurodegenerative pathways may open a novel avenue to establish an early intervention strategy for AD.

2. Direct Oxidation of RNA Species

2.1. Susceptibility of RNA to Oxidative Damage. Compared to oxidative DNA damage, far fewer studies have focused on oxidative damage to RNA, and only limited kinds of oxidatively modified bases in RNA have been reported previously [28–30]. Among multiple adducts of nucleoside oxidation, 8-oxo-deoxyguanosine (8-oxodGuo) and 8-oxoGua are two of the best characterized and studied forms of DNA and RNA oxidation, respectively [31, 32]. Cellular abundance, location, lack of coating histone, and its single-stranded structure make RNA more susceptible to OS than DNA [33–35] (Table 1). Accordingly, greater oxidation to RNA than to DNA has been shown in studies with isolated DNA and RNA as well as in several kinds of cell lines and tissues [8].

2.2. Susceptibility to Oxidative Damage in Different RNA Species

2.2.1. Messenger RNA (mRNA). The extent of oxidative RNA damage varies greatly among different types of RNA in a manner that appears to show greater oxidative RNA damage in lesser association with RNA binding proteins [10]. For example, poly (A)+ mRNA is found to have fivefold higher levels of 8-oxoGua than total RNA that consists mostly of ribosomal RNA (rRNA) [9]. In the AD brain, northwestern blotting with a monoclonal anti-8-oxoGua antibody shows that a significant amount of brain poly (A)+ mRNA species are oxidized. While the identified oxidized mRNAs reveal that some species are more susceptible to OS in AD, no common motifs or structures were found in the oxidatively susceptible mRNA species in the AD brain [36]. Some of the identified known oxidized transcripts are related to the pathophysiology of AD, which included p21ras, mitogen-activated protein kinase (MAPK) kinase 1, carbonyl reductase, copper/zinc superoxide dismutase (SOD1), apolipoprotein D, and calpains, but not amyloid-β protein precursor (APP) or tau [36].

2.2.2. Ribosomal RNA (rRNA) and Transfer RNA (tRNA). In the AD brain, rRNA, extremely abundant in neurons, contains 8-oxoGua [37, 38]. Remarkably, rRNA shows higher binding capacity to redox-active iron than tRNA, and consequently, the oxidation of rRNA by the Fenton chemistry forms 13 times more 8-oxoGua than tRNA [37].

2.2.3. MicroRNA (miRNA). MicroRNAs (miRNAs) are small noncoding RNAs containing approximately 22 nucleotides, and they bind to complementary sequences in the three prime untranslated regions (3'UTRs) of target mRNA transcripts, thereby inhibiting mRNA translation or promoting mRNA degradation [39]. In the biogenesis pathway, miRNAs are transcribed from genomic loci as long as primary strands (pri-miRNAs) that undergo cleavage to precursor hairpins (pre-miRNAs) in the nucleus before being exported to the cytoplasm. PremiRNAs are further cleaved into double-stranded miRNA:miRNA* duplexes and loaded into the RNA-induced silencing complex (RISC) containing an Argonaute (Ago) family protein as a core component. Finally, single-stranded mature miRNAs are completed by unwinding of the duplexes [40]. As a result, the repressive functions of the RISC and mature miRNAs themselves have been primarily associated with the cytoplasm, while several mature miRNAs are expressed also in the nucleus and nucleolus [41, 42]. Given cytoplasmic predominance of the subcellular localization and the single-stranded form, the mature miRNAs might be highly vulnerable to reactive oxygen species (ROS) (Table 1). Surprisingly, up to hundreds of miRNAs, besides 22 tRNAs and two rRNAs, have been identified from mitochondria, the major source of ROS [41]. Furthermore, miRNAs are often relatively long lived, and their half-lives reported to be ranged from 28 to 220 h, which is roughly 2- to 20-fold longer than that of typical mRNAs (about 10 h) [43]. Taken together, these findings support the possibility that miRNAs have abundant opportunities to be attacked by ROS.

Wang et al. have demonstrated that oxidized miRNAs containing 8-oxoGua are produced in vitro through hydrogen peroxide (H2O2) treatment in a rat heart cell line as well as in vivo in the hearts of a mouse model of ischemia/reperfusion [19]. Indeed, miR-184 is the most highly oxidized but other oxidized forms of miRNAs are detected, i.e., oxidized
which is formed from the reaction of highly di

ROS as well as supplying redox-active iron into the cytosol

In the AD brain, malfunctioning mitochondria likely play a central role in producing abundant

ROS: reactive oxygen species.

miR-135a, miR-139, miR-204, miR-21, miR-23a, miR-290, miR-29a, and miR-30c. Therefore, not all miRNAs are oxidized in response to ROS stimulation, whereas several miRNAs are more susceptible to the oxidative modification. It remains to be determined whether there exists a common motif and sequence for the selective oxidation of miRNAs [19]. Although oxidized miRNAs are not identified in the human brain diseases at the current moment, possible involvement of the oxidized miRNAs in AD and related neurodegeneration is strongly suggested [8, 44, 45]. Additionally, direct oxidative modifications to other noncoding RNAs such as small nuclear RNAs, small nucleolar RNAs, long noncoding RNAs, and circular RNAs are not reported, while the role of these RNA species in the nervous system has recently drawn growing attention [46, 47].

2.3. Sources of Reactive Oxygen Species (ROS) Responsible for RNA Oxidation

2.3.1. ROS of Mitochondrial Origin and Fenton Reaction. The brain is particularly vulnerable to oxidative damage because of its high oxygen consumption rate (accounting for 20-25% of total body oxygen consumption but less than 2% of total body weight), high content of fatty acids and transition metals, and relative paucity of antioxidant enzymes compared with other organs (e.g., the content of catalase in the brain is only 10-20% of the liver and heart) [8, 48] (Table 1). Given this environment, neurons are continuously exposed to ROS such as superoxide (O$_2^-$), H$_2$O$_2$, and hydroxyl radical (·OH) that are produced from the mitochondrial electron transport chain through the normal cellular metabolism [49-51]. Among them, highly reactive ·OH can diffuse through the tissue only in the order of several nanometers [52], while O$_2^-$ is hardly permeable through cell membranes [53]. In consideration of the widespread damage to cytoplasmic RNA in AD [54, 55], RNA species are likely attacked by ·OH, which is formed from the reaction of highly diffusible H$_2$O$_2$ [56] with redox-active metals through the Fenton chemistry [37]. In the AD brain, malfunctioning mitochondria likely play a central role in producing abundant ROS as well as supplying redox-active iron into the cytosol [57, 58]. Indeed, ribosomes purified from the AD hippocampus contain was significantly higher levels of redox-active iron compared to controls, and the iron is bound to rRNA [37]. Therefore, mitochondrial abnormalities coupled with dysregulation of metal homeostasis are key features closely associated with ROS formation responsible for the RNA oxidation in AD [59].

2.3.2. Mode of Oxidized miRNA Generation. The concept that ROS originates from the mitochondria and becomes harmful when they are coupled with redox-active metals is fully compatible with the mode of the oxidized miRNA generation in the cellular model reported by Wang et al. [19]. In fact, miRNAs remain almost intact after incubation with H$_2$O$_2$ or redox-active iron (Fe$^{3+}$) alone. However, when miRNAs were incubated in a mixture of H$_2$O$_2$ and Fe$^{3+}$ along with the reducing agent ascorbate, their oxidation substantially occurred, which indicates that oxidatively modified miRNAs are generated by ·OH via the Fenton reaction [19].

2.4. Biological Consequence of Oxidized RNA

2.4.1. Oxidized mRNA. Although guanine is the most reactive of the nucleic acid bases, not only 8-oxoGuo but also 8-oxo-adenosine, 5-hydroxycytidine, and 5-hydroxuryridine have been identified in oxidized RNA [28]. These oxidized nucleosides may have altered pairing capacity and thus be at the origin of erroneous protein production. Indeed, the 8-oxoGuo can pair with both adenine and cytosine, and thus oxidized RNA compromises the accuracy of translation [60, 61]. The oxidized bases in miRNAs in cell lines cause ribosomal stalling on the transcripts leading to a decreased rate of full-length peptide synthesis [9, 62, 63], as well as synthesis of truncated, nonfunctional peptides, or mutated peptides [64]. Moreover, strand scission is proposed to result from as many as 40% of reactions of ·OH with RNA [65]. Recently, a distinct pathway between heavily oxidized mRNA and apoptotic cell death has been established. Mechanistically, specific binding of poly(C)-binding protein 1 (PCB1) to oxidized mRNA in which two 8-oxoGuo residues are located nearby induces caspase-3 activation and subsequent apoptosis [16].

2.4.2. Oxidized rRNA. The biological consequence of rRNA oxidation has also been investigated in vitro using translation assays with oxidized ribosomes from rabbit reticulocytes and shows a significant reduction of protein synthesis [37]. Notably, studies on brains of subjects with AD and MCI have demonstrated ribosomal dysfunction associated with oxidative RNA damage. Isolated polyribosome complexes from AD and MCI brains show a decreased rate and capability for protein synthesis without alteration in the polyribosome content [38, 66]. A variety of ways that oxidative damage to

Table 1: Reasons why RNA species in human brain are vulnerable to oxidative insults.

| RNA species          | (i) Abundance in a cell | (ii) Mostly single-stranded form and less protection by proteins | (iii) Localization in the vicinity of mitochondria, the major source of ROS | (iv) No known repair mechanisms for oxidized RNA |
|----------------------|-------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|
| Human brain          | (i) High oxygen consumption rate | (ii) High content of easily peroxidizable polyunsaturated fatty acids | (iii) High content of transition metals that catalyze ROS-generating reactions | (iv) Low content of antioxidant enzyme catalase |

ROS: reactive oxygen species.
the functional domain of rRNA which affects translation are suggested: (i) inhibiting ribosomal assembly, resulting in the nonfunctional subunit; (ii) interfering with codon-anticodon interaction or with binding of aminocetyl-tRNA, causing mis-coding or ribosomal stalling, and (iii) blocking elongation of nascent peptide and stalling the ribosome [10].

2.4.3. Oxidized tRNA. Oxidative damage to tRNA may cause defects in codon-anticodon pairing or in aminocylation, potentially leading to production of miscoded proteins [10]. Moreover, cleavage and fragmentation of tRNA induced by oxidative stress are observed in cell lines [67], which promotes formation of stress granules [10]. Like oxidized mRNA, a mechanism inducing apoptosis has been suggested by oxidized tRNA. Because tRNA is accessible in the mitochondrial intermembrane space, oxidized tRNA forms cross-linked complex with cytochrome c (cyt c), which facilitates cyt c release from the mitochondria and subsequently induces apoptosis [68].

2.4.4. Oxidized miRNA. A recent discovery of oxidized miRNAs opens new avenue in the research field of RNA oxidation. The oxidized miRNA causes misrecognizing target mRNAs, resulting in downregulation in synthesis of particular proteins and potentially inducing cellular crucial events [19]. Among several oxidized miRNAs, oxidized miR-184 containing 8-oxo-Guo shows such a prominent influence to the cell functions. Indeed, oxidized miR-184 associates with the 3′UTRs of B cell lymphoma-extra-large (Bcl-xL) and Bcl-2-like protein 2 (Bcl-w) that are not its native targets. Subsequent reduction in Bcl-xL and Bcl-w is responsible for the cells undergoing apoptosis [19].

2.5. Coping with RNA Damage

2.5.1. Degradation. Degradation of RNA plays a central role in RNA metabolism, and damaged RNA can be removed through degradation by ribonucleases (RNase), but selective degradation activity for oxidized RNA has not been established for known RNases [34, 69]. Because absence of no-go decay factors causes an accumulation of 8-oxoGuo-containing mRNA in yeast, the oxidized mRNA is likely subjected to degradation through no-go decay, a ribosome-based mRNA surveillance mechanism [9].

2.5.2. Repair Mechanisms. Alkylation damage in RNA is repaired by the same mechanism as a DNA-repair, catalyzed in the bacterium *Escherichia coli* by the enzyme AlkB, and in humans by the related protein [70]. However, specific repair mechanism for oxidized RNA, unlike DNA, has not been reported.

2.5.3. Avoidance of Oxidized Ribonucleotides Incorporation. The mechanism avoiding incorporation of the oxidized nucleotide into DNA and RNA is involved in coping with nucleic acid damage [33, 34, 71, 72]. MutI homologue 1 (MTH1) and Nudix type 5 (NUDT5) proteins participate in this error-avoiding mechanism by hydrolyzing the oxidized nucleoside diphosphates and/or triphosphates to the monophosphates [60, 61, 73]. Indeed, the expression of MTH1 is increased in vulnerable neurons in AD [74] and PD [75], indicating a compensatory upregulation of the MTH1

### Table 2: Oxidized RNA species potentially induce apoptosis.

| RNA species                        | Mechanism inducing apoptosis by oxidized RNAs                                                                 |
|------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Oxidized messenger RNA (mRNA)      | Specific binding of poly(C)-binding protein 1 (PCB1) to heavily oxidized mRNA carrying two 8-oxo-guanine residues at the 9th and 15th positions triggers caspase-3 activation and subsequent apoptosis. |
| Oxidized transfer RNA (tRNA)       | Because tRNA is accessible in the mitochondrial intermembrane space, oxidation of tRNA can be catalyzed by cytochrome c (cyt c) and leads to the formation of cross-linking complex between tRNA and cyt c, then, oxidized tRNA facilitates cyt c release from mitochondria and subsequently induces apoptosis. |
| Oxidized microRNA (miRNA)          | Oxidized miRNA-184 containing 8-oxo-guanosine associates with the 3′ UTRs of Bcl-xL and Bcl-w that are not its native targets. Subsequent reduction in Bcl-xL and Bcl-w is responsible for the cells undergoing apoptosis. |

3′ UTRs: three prime untranslated regions.
| miRNA      | Up- or downregulated in brains with AD pathology                                                                 | Target gene | Specific function and association with OS regulation clarified by cellular and animal experiments | Ref                  |
|------------|------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------------------------------------------|----------------------|
| miR-107    | Downregulated in the temporal cortex at Braak stages III/IV of MCI subjects                                    | BACE1       | MiR-107 decreases BACE-1 mRNA levels by binding to the 3’ UTR of BACE1, hence decreases the production of Aβ. OS served as the key trigger to downregulate miR-107 by cell-derived soluble Aβ. Overexpression of miR-125b promotes APP and BACE1 expression and Aβ production and apoptosis by targeting SPHK1 through inflammation (via increase in TNF-α and IL-6) and OS (via decrease in SOD). Mir-125b promotes tau phosphorylation by targeting NCAM. MiRNA-146a is NFκB-sensitive and activates inflammation by targeting 3’ UTR of CFH, an important repressor of the inflammatory response of the brain. | [92, 115, 116] |
| miR-125b   | Upregulated in the frontal cortex at Braak stages III/IV of non-demented and early AD subjects                   | SPHK1, NCAM | Overexpression of miR-125b induces tau phosphorylation by targeting ROCK1 via inhibition of PTEN. MiR-125b promotes tau phosphorylation by targeting NCAM. | [93, 99, 100] |
| miR-146a   | Upregulated in the hippocampus at Braak stages III/IV of preclinical or early AD subjects                      | CFH, ROCK1, SOD2 | Overexpression of miR-146a induces tau phosphorylation by targeting ROCK1 via inhibition of PTEN. MiR-125b promotes tau phosphorylation by targeting NCAM. MiRNA-146a is NFκB-sensitive and activates inflammation by targeting 3’ UTR of CFH, an important repressor of the inflammatory response of the brain. | [94, 101–103] |
| miR-200c   | Upregulated in the hippocampus at Braak stages III/IV of non-demented and early AD subjects                    | PTEN, S6K1 | MiR-200c supports cell survival and neurite outgrowth of cultured neuron by targeting PTEN. MiR-200c reduces Aβ secretion by targeting S6K1 via reduction of IRS-1pSer and promoting insulin signaling. MiR-200c is upregulated by ROS in primary hippocampal neuron. Soluble Aβ leads to NMDAR overactivation, excessive calcium influx, mitochondrion-derived ROS production, and upregulation of miR-210. MiR-210 targets ISCU1/2 and COX10 that have important roles in mitochondrial respiration and function. Overexpression of miR-26b leads to aberrant cell cycle re-entry and increased tau-phosphorylation by targeting RB1 via activation of RB1/E2F cell cycle and CDK5. Sequence-specific inhibition of miR-26b in culture is neuroprotective against OS. Overexpression of miR-30e increases the levels of SOD, GSH, and GSH-PX and decreases ROS levels by targeting SNAI1 through decreasing TGF-β and SMAD2 expression and increasing NOX4 expression. Overexpression of miR-34a increases the levels of an adaptor protein p66shc and reduces tolerance to OS by targeting SIRT1. Conditional miR-34a overexpression mouse shows cognitive impairment associated with accumulation of intracellular Aβ and tau hyperphosphorylation possibly through targeting | [93, 111–113] |
| miR-210    | Downregulated in the hippocampus at Braak stages III/IV of non-demented and early AD subjects                   | ISCU1/2, COX10 | Overexpression of miR-26b leads to aberrant cell cycle re-entry and increased tau-phosphorylation by targeting RB1 via activation of RB1/E2F cell cycle and CDK5. Sequence-specific inhibition of miR-26b in culture is neuroprotective against OS. Overexpression of miR-30e increases the levels of SOD, GSH, and GSH-PX and decreases ROS levels by targeting SNAI1 through decreasing TGF-β and SMAD2 expression and increasing NOX4 expression. Overexpression of miR-34a increases the levels of an adaptor protein p66shc and reduces tolerance to OS by targeting SIRT1. Conditional miR-34a overexpression mouse shows cognitive impairment associated with accumulation of intracellular Aβ and tau hyperphosphorylation possibly through targeting | [93, 116] |
| miR-26b    | Upregulated in the temporal cortex at Braak stage III of patients with MCI                                     | RB1         | | [95] |
| miR-30e    | Upregulated in the hippocampus at Braak stages III/IV of non-demented and early AD subjects                    | SNAI1       | Overexpression of miR-30e increases the levels of SOD, GSH, and GSH-PX and decreases ROS levels by targeting SNAI1 through decreasing TGF-β and SMAD2 expression and increasing NOX4 expression. | [93, 110] |
| miR-34a    | Upregulated in the frontal cortex and hippocampus at Braak stages III/IV of non-demented and early AD subjects. | ADAM10, NMDAR 2B, Trem2, BCL2 | Overexpression of miR-34a increases the levels of an adaptor protein p66shc and reduces tolerance to OS by targeting SIRT1. Conditional miR-34a overexpression mouse shows cognitive impairment associated with accumulation of intracellular Aβ and tau hyperphosphorylation possibly through targeting | [93, 104–108] |
### Table 3: Continued.

| miRNA   | Up- or downregulated in brains with AD pathology | Target gene | Specific function and association with OS regulation clarified by cellular and animal experiments | Ref |
|---------|-------------------------------------------------|-------------|-------------------------------------------------------------------------------------------------|-----|
| miR-34c | Upregulated in the hippocampus at BraaK stages III/IV of early AD subjects | SYT1        | ADAM10, NMDAR 2B, and SIRT1. MiR-34a targets also the amyloid sensing- and clearance receptor protein TREM2 as well as anti-apoptotic protein BCL2. Overexpression of miR-34c mediates synaptic and memory deficits by targeting SYT1 through ROS generation, JNK activation, and p53 accumulation. MiR-485 decreases BACE1 mRNA levels by binding to BACE1 exon 6, hence decreases the production of Aβ. MiR-485 upregulation alleviates ischemia-reperfusion injury by targeting RAC1 via NOTCH2 signaling, which are evidenced by improved cell viability, decreased OS markers, and reduced apoptotic rate. | [94, 109] |
| miR-485 | Downregulated in the frontal cortex at BraaK stage III of early AD subjects | BACE1, RAC1 | MiR-485 mediates synaptic and memory deficits by targeting SYT1 through ROS generation, JNK activation, and p53 accumulation. MiR-485 decreases BACE1 mRNA levels by binding to BACE1 exon 6, hence decreases the production of Aβ. MiR-485 upregulation alleviates ischemia-reperfusion injury by targeting RAC1 via NOTCH2 signaling, which are evidenced by improved cell viability, decreased OS markers, and reduced apoptotic rate. | [96, 118, 119] |

3' UTR, three prime untranslated region; Aβ, amyloid-β; ADAM10, A Disintegrin and metalloproteinase domain-containing protein 10; APP, amyloid precursor protein; BACE1, β-site amyloid precursor protein-cleaving enzyme 1; BCL2, B-cell lymphoma 2; CDK5, cyclin-dependent kinase 5; CFH, complement factor H; COX10, cytochrome c oxidase assembly protein; ER, endoplasmic reticulum; GSH, glutathione; GSH-PX, glutathione-peroxidase; IL-6, interleukin-6; IRS-1pSer, insulin receptor substrate 1 at serine residues; ISCU1/2, iron-sulfur cluster scaffold homolog 1/2; JNK, Jun amino terminal kinase; MCI, mild cognitive impairment; NCAM, neural cell adhesion molecule; NF-κB, nuclear transcription factor κB; NMDAR, N-methyl-D-aspartate receptor; NOTCH2, neurogenic locus notch homolog protein 2; NOX4, NADPH oxidase 4; p66shc, 66 kDa proto-oncogene Src homologous-collagen homologue; PSEN1, presenilin-1; PTEN, phosphatase and tensin homolog; RAC1, RAS-related C3 botulinus toxin substrate 1; RB1, retinoblastoma 1; ROCK1, rho-associated, coiled-coil containing protein kinase 1; ROS, reactive oxygen species; S6K1, S6 kinase 1; SIRT1, silent mating type information regulation 2 homolog (sirtuin) 1; SMAD2, mothers against decapentaplegic homolog 2; SPHK1, sphingosine kinase 1; SYT1, synaptic protein 1; TGF, transforming growth factor; TNF-α, tumor necrosis factor-α; TREM2, triggering receptor expressed in myeloid cells 2.

against OS. Moreover, several enzymes involved in the nucleotide metabolism show a discriminative activity against the oxidized nucleotides. Guanylate kinase (GK), converting GMP to GDP, is inactive on 8-oxo-GMP [76]. Similarly, ribonucleotide reductase (RNR), catalyzing reduction of four naturally occurring ribonucleoside diphosphates, is inactive on 8-oxo-GDP [76]. The final gatekeeper is RNA polymerase that incorporates 8-oxo-GTP into RNA at a much lower rate compared to the normal GTP incorporation [34, 60, 72].

### 2.5.4. Proteins Binding Specifically to Oxidized RNA.**

Proteins that bind specifically to 8-oxoGuo-containing RNA have been reported, namely, polynucleotide phosphorylase (PNPase) [77, 78], Y box-binding protein 1 (YB-1) [79], and AU-rich element RNA binding protein 1 (Aufl) [also called heterogeneous nuclear ribonucleoprotein D0 (HNRNPD)] [80, 81]. It has been proposed that these proteins are able to recognize and discriminate the oxidized RNA molecule from normal ones, thus contributing to the fidelity of translation in cells by sequestrating the oxidized RNA from the translational machinery [77–80].

### 2.5.5. Coping with Oxidative miRNA Damage.**

Compared to the biogenesis and activity, the process of degradation of miRNAs has received less attention. While miRNAs are globally stable, individual miRNAs display rapid decay dynamics in some specific situations, as occurs for a few neuron-enriched miRNAs, but not constitutively expressed miRNAs, and for mature miRNAs, but not the miRNA precursors [43]. Although several miRNA-degrading enzymes have been identified, including both 3′-to-5′ and 5′-to-3′exoribonuclease [43, 82], whether they are less or more efficient for oxidized miRNAs is unknown. Among them, the human PNPase degrades certain mature miRNAs in human melanoma cells [82] and may be involved in oxidized miRNA degradation [77, 78]. A recent comprehensive review has concluded that how cells cope with oxidative damage to miRNAs is unclear, and whether they have evolved pathways to degrade or repair them should be the subject of future research [83].

### 2.6. Therapeutic Interventions against Oxidized RNA Species.**

Several experimental studies on human subjects and animal models have demonstrated successful interventions including nonpharmacological and pharmacological approaches towards reduction of oxidized RNA. Indeed, the efficacious interventions are caloric restriction and exercise in human subjects [84], as well as administrations with antioxidants and anti-inflammatory agents such as acetyl-l-carnitine [85], α-linolenic acid [86], α-lipoic acid [85], docosahexaenoic acid (DHA) [86], indomethacin [87], selenium [14], and vitamin E [88] in experimental animals. Antioxidants may reduce miRNA oxidation as well. Administration of N-acetylcysteine (NAC) reduces oxidized miR-184 and attenuates the reductions in Bcl-xL and Bcl-w and consequently prevents apoptosis both in the rat heart cell line and in the hearts of a mouse model of ischemia/reperfusion [19].
Overexpressing human MTH1 in a transgenic mouse model significantly reduced 8-oxoGuo in the brain [89].

### 3. microRNAs and Oxidative Stress Regulation

#### 3.1. Interplay between miRNAs and Oxidative Stress (OS) Affects Neurodegeneration

miRNAs are embedded in complex regulatory networks, since a single miRNA can regulate up to hundreds of target mRNAs coding for different proteins [39, 90]. It has been demonstrated that miRNAs regulate lots of genes involved in the OS response, and conversely, OS affects expression levels of multiple miRNAs. Indeed, 27 different miRNAs are associated with generation but 11 different miRNAs are associated with reduction of OS. In downstream of OS, induced expression of 56 miRNAs, while reduced expression of 32 miRNAs, is observed [25]. Moreover, dysregulation of miRNAs has been implicated in neurodegenerative disorders such as AD, PD, amyotrophic lateral sclerosis, Huntington’s disease, and prion disorders [27, 91]. Although the interrelations among miRNAs, OS, and neurodegeneration are often considered separately, several miRNAs embedded in OS regulation or OS targets are involved also in known pathways of neurodegeneration such as mitochondrial dysfunction, inflammation, and protein misfolding. Some classes of miRNAs accelerate these cellular anomalies, whereas others act in a counterregulatory, protective role. Also, changes in levels of certain species of miRNAs can be a consequence of the abovementioned anomalies [17, 27].

#### 3.2. Specific miRNAs Associated with Both OS and Alzheimer’s Disease (AD)

##### 3.2.1. Altered miRNAs in the AD Brain at Braak Stages III/IV

The roles of individual miRNAs, i.e., seven upregulated miRNAs (miR-125b, miR-146a, miR-200c, miR-26b, miR-30e, miR-34a, miR-34c) and three downregulated miRNAs (miR-107, miR-210, miR-485) that are relevant to both OS and neurodegenerative pathways in AD are summarized in Table 3. Of note, all the alterations of these miRNAs are demonstrated in the human brain with early AD pathology at Braak stages III and IV [92–96] that are not a substrate for profound cognitive impairment [97] and largely correspond to MCI [98].

##### 3.2.2. Upregulated miRNAs in the AD Brain at Braak Stages III/IV

A synergistic effect mechanism of accelerated AD pathology and OS in neurodegeneration is found in several upregulated miRNAs listed in Table 3, i.e., miR-125b [99, 100], miR-146a [101–103], miR-26b [95], and miR-34a [104–108]. Upregulation of these miRNAs leads to Aβ production and/or tau-phosphorylation and an increase in vulnerability to OS. Upregulation of miR-34c increases ROS production and mediates synaptic deficits through the ROS-Jun amino terminal kinase (JNK)-p53 pathway [109].

---

**Figure 1:** Overview of interrelations among oxidative stress, RNA species modification/dysregulation, and neurodegenerative changes in Alzheimer’s disease. Oxidative stress can induce two modes of oxidative insults on RNA species, i.e., direct oxidation of RNAs and oxidative dysregulation of the microRNA (miRNAs) expression. These modifications and dysregulations of RNAs potentially induce neuronal apoptosis or nonlethal neuronal dysfunction as well as amyloid β overproduction and tau hyperphosphorylation. Besides these changes as consequences of oxidative stress, altered expressions of some miRNAs are associated with an acceleration of oxidative stress, while those of others are associated with a compensatory reduction of oxidative stress. Of note, dysmetabolism of amyloid β can be a cause or a consequence of oxidative stress. *Oxidized transfer RNAs and oxidized microRNAs have been reported only in cellular and animal models, but the other changes in RNAs shown in this figure have been found in the brains of Alzheimer’s disease.*
In contrast, upregulation of miR-30e, being found in the hippocampus of AD [93], increases antioxidant enzymes such as SOD, glutathione (GSH), and glutathione-peroxidase (GSH-PX) and decreases ROS [110], suggesting compensatory regulation of the miRNA in the AD brain. The role of miR-200c in the pathophysiology is more complicated. MiR-200c is upregulated by Aβ-induced endoplasmic reticulum (ER) stress or OS [111, 112] and able to reduce Aβ secretion [113], suggesting a compensatory role. Indeed, upregulation of miR-200c is observed in the hippocampus of AD subjects [93] and in the cortices of APP transgenic mice at an early period of Aβ deposition [113]. In epilepsy model rats, however, downregulation of miR-200c is neuroprotective. It increases SOD and GSH-PX activities and decreases apoptosis of hippocampal neurons by upregulation of its target reversion-inducing cysteine-rich protein with kazal motifs (RECK) via inactivating protein kinase B (AKT) signaling [114].

3.2.3. Downregulated miRNAs in the AD Brain at Braak Stages III/IV. As for downregulated miRNAs listed in Table 3, each specific miRNA shows its own mode of relevance to the disease pathogenesis. OS triggers downregulation of miR-107 that normally represses Aβ production, and downregulation of miR-107 in AD is associated with an accumulation of Aβ [115, 116]. Because cell-derived soluble Aβ induces further OS [117], a vicious cycle promoting OS and Aβ production is formed. Similarly, miR-485 that normally represses Aβ production and silences OS [118, 119] is downregulated in the cortex of AD [96], where altered miR-485 exacerbates neurodegeneration through both excess of Aβ and OS. Conversely, downregulation of miR-210 in the hippocampus of AD [93] may represent compensatory regulation of the miRNA in the AD brain. Because soluble Aβ leads to upregulation of miR-210 that inhibits the mitochondrial respiration and function [116], downregulation of miR-210 should be neuroprotective through alleviating Aβ toxicity and OS silencing.

3.2.4. Other Altered miRNAs in the AD Brain. Downregulation of miR-128 is observed in the hippocampus at the Braak stage VI of advanced AD patients, but not at the Braak stage III/IV [94]. Indeed, miR-128 promotes Aβ-mediated cytotoxicity by targeting peroxisome proliferator activated receptor-γ (PPAR-γ) via activation of nuclear transcription factor κB (NF-κB) [120]. Also, miR-128 promotes OS by targeting sirtuin 1 (SIRT1) [121], indicating that downregulation of miR-128 in late-stage AD seems to be a compensatory regulation against Aβ pathology and OS. MiR-15b also downregulated in the temporal cortex and hippocampus of patients with AD. In contrast to miR-128, miR-15b reduces Aβ accumulation through directly targeting 3′ UTRs of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) and NF-κB [122] and counteracting senescence associated mitochondrial dysfunction and ROS generation by targeting stress-induced SIRT4 [123]. Therefore, downregulation of miR-15b in AD is associated with an acceleration of both Aβ pathology and OS.

The interrelations among OS, RNA species modification/dysregulation, and neurodegenerative changes in AD are summarized in Figure 1.

3.2.5. Altered miRNAs in the Mouse Model of AD. Downregulation of miR-20a is observed in the transgenic mouse model of AD carrying Swedish double mutation (K670N/M671L) of the amyloid precursor protein (APP) and M146L mutation of the presenilin-1 (PSEN1) (APPSwe/PSEN1M146L) [108]. While ROS upregulates miR-20a in primary hippocampal neuron [124], miR-20a reduces Aβ by targeting APP [125], indicating a decrease in the protective function of miR-20a in this model. Conversely, miR-98 is upregulated in the APPSwe/PSEN1M146L mouse model [108], which seems to represent a compensatory mechanism.
against AD and OS. MiR-98 decreases the production of APP and Aβ and improves OS and mitochondrial dysfunction targeting hairy and enhancer of split- (Hes-) related with the YRPW motif protein 2 (HEY2) via inactivation of the Notch signaling pathway [126]. Similarly, a protective function of miR-330 targeting vav guanine nucleotide exchange factor 1 (VAV1) is reported in the AD mouse model through the MAPK signaling pathway. Upregulation of miR-330 reduces Aβ production and alleviates OS and mitochondrial dysfunction in AD [127]. In the transgenic mouse model of AD carrying APP Swedish mutation and PSEN1 lacking exon 9 (APPSwe/PSEN1Δ9), OS-associated miR-34a, miR-34c, and miR-98 are abnormally expressed in the animal between 3 and 6 months of age [128] when initial Aβ depositions start in the hippocampus [129]. Taken together, studies on the postmortem human brain and transgenic animal model consistently suggest the altered expression of the OS-associated miRNAs as an early-stage event of AD.

3.3. Neuroprotective Function of REST and miRNAs

3.3.1. A Transcriptional Repressor, REST: AD and OS. The restrictive element-1 silencing transcription factor (REST), also known as neuron-restrictive silencing factor (NRSF), has been shown to function as a regulator of neuronal genes involved in neurogenesis and neuronal differentiation. However, recently accumulated findings strongly indicate that REST is not only a classical repressor to maintain normal differentiation. How- ever, REST is increased with aging in brains of cognitively normal elderly. However, in brains of patients with MCI and AD, a significant reduction in REST has been found in cortical and hippocampal neurons, where nuclear REST levels are positively correlated with a global cognitive measure. Of particular note, elevated REST levels are associated with preservation of the cognitive function even in the presence of AD pathology [132]. Indeed, chromatim immunoprecipitation with deep sequencing shows that REST represses proapoptotic genes, e.g., FAS, FAS-associated death domain protein (FADD), TNF receptor-associated death domain protein (TRDD), Bcl-2-associated X protein (BAX), and cytochrome c, as well as AD pathology-associated genes, e.g., presenilin-2 (PSEN2) and presenilin enhancer 2 (PSE- NEN) implicated in Aβ generation and MAPK implicated in tau phosphorylation. Simultaneously, REST induces the expression of forkhead box O (FOXO) transcription factors that mediate OS resistance and the antioxidant enzymes catalase and SOD1. That REST potently protects neurons from OS and Aβ toxicity is rigorously confirmed by experiments on conditional REST knockout mice and nematode Caenorhabditis elegans (C. elegans) models with a functional orthologue of REST and SPR-4 [132].

3.3.2. Rest and miRNAs. As REST has been shown to mediate the temporal and cellular expression of several classes of noncoding RNAs including miRNAs [133], the loss of REST in AD might disturb the network of miRNAs. Quite recently, loss of REST causes upregulation of miR-124 and downregulation of its target protein phosphatase 1 (PTPN1) and disrupted miR-124/PTPN1 signaling that induces AD-like tau pathology in mice via activation of glycogen synthase kinase 3 (GSK-3) and inactivation of protein phosphatase 2A (PP2A) [134]. Conversely, REST is regulated by some cytokines/regulators such as miRNAs [130]. Indeed, miR-124 and miR-9 target REST and form self-enforcing loops together with the poly(ADP-ribose) polymerase (PARP) to control neuronal conversion and maturation. In a double negative feedback loop consisting of PTB, miR-124, and REST (PTB-REST-miR-124 loop), REST represses miR-124, which in turn dismantles multiple components of the REST complex, and the RNA binding protein PTB serves both as a substrate for and a key inhibitor to the miR-124 targeting [135]. As is the case with the process of neurogenesis, the miRNA system likely acts both upstream and downstream of the REST expression in the aging brain, where the miRNA system participates in fine tuning of the gene to distinguish neuroprotection from neurodegeneration.

3.4. MiRNAs Mediates Hormesis under OS

3.4.1. Hormesis and OS. The relationship between the strength of a stressor and its biological effects on a physiological phenotype is not linear, but biphasic. This process is known as hormesis, whereby exposure to a low dose of a potentially harmful stressor promotes adaptive changes to the cells, organs, and living body that enables it to better tolerate subsequent stress. When we consider the hormetic response in association with neuronal adaptation to stressors, it is helpful to introduce the concepts of “neurohormesis” by Mattson [136] and “mitohormesis” by Ristow [137] in the context of maintaining cognitive health. Because these concepts indicate that moderate levels of OS are beneficial to the biological system through the adaptive preconditioning, further investigation to understand the molecular mechanisms of the regulatory hormesis may give hints on developing a new therapeutic approach for neurodegenerative diseases.

3.4.2. Hormesis and miRNAs. Recent studies indicate an involvement of changes in miRNAs in the adaptive response of hormesis or preconditioning. In an experiment using C. elegans exposed to nicotine in the period of postembryonic stages, the hormetic response in locomotive speed of the worm was observed by low and high dose of nicotine exposure. Of note, there was a dose-dependent increase in the degree of fold change (1 vs. 3.4-fold) and the number (1.3% vs. 16.4%) of the differentially altered miRNAs in the worm treated with low- and high-dose nicotine [138]. These observations support a speculation that miRNAs as a system mediates hormesis (Figure 2). In another study using C. elegans, an antibiotic enoxacin extends the lifespan of the worms by downregulating miR-34-5p. The longevity effects associated with downregulated miR-34 are abrogated by the antioxidant NAC, indicating that the mechanism of promoting longevity matches well with a prooxidant-mediated mitohormetic response [139]. Also, the involvement of miRNAs in the hormetic activation of the antioxidant system is suggested in an
experiment of preharvest ultraviolet C (UV-C) treatment that attenuates postharvest senescence of stored strawberry fruit. Indeed, miR-159 and miR-398 are downregulated by UV-C, and that their respective targets are upregulated at the early stage of storage with enhancement of the activity of antioxidant enzymes. The initial burst of ROS primes the fruit in an antioxidative activated state via ROS-mediated feedback control with posttranscriptional involvement of miRNAs [140].

3.4.3. Ischemic Preconditioning and miRNAs. Neuroprotective regulation of miRNAs is induced also in the early phase of ischemic preconditioning. MiR-200c, upregulated in the hippocampus of AD subjects [93] and in the cortices of APP transgenic mice at early period of Aβ deposition [113], is involved among miRNAs that upregulated at 3 hours after cerebral ischemic preconditioning in mice [141]. Of note, the protective function of miR-200c upregulation is mediated by targeting prolyl hydroxylase 2 (PHD2, also known as EGLN1), a sensor of oxygen and OS [142]. Similarly, downregulation of miR-15b, observed in the temporal cortex of AD patients [143], is associated with preconditioning by a volatile anesthetic sevoflurane against cerebral ischemic injury in rats by sustained expression of its target Bcl-2, an antiapoptotic protein [144].

4. MicroRNAs in Diagnosis and Therapy for Alzheimer’s Disease

4.1. MiRNAs as a Diagnostic Tool for AD

4.1.1. Circulating miRNAs in Bodily Fluids. MiRNAs are not only detected in tissue but also in bodily fluids such as blood plasma and serum, cerebrospinal fluid (CSF), urine, and saliva. These miRNAs are collectively known as circulating miRNAs. miRNAs are actively and selectively excreted from cell cytoplasm to bodily fluids through exosomes, microparticles, apoptotic cell bodies, or excreted as microvesicle free miRNAs that are associated with diverse proteins such as Ago and high-density lipoprotein. Also, they can be passively excreted into bodily fluids as a result of apoptosis, metastasis, and inflammation [90]. It has been suggested that miRNAs from the brain are able to cross the blood-brain barrier (BBB) into peripheral circulation using exosomes [145, 146].

4.1.2. Circulating miRNAs in AD. According to a recent review on circulating miRNAs, collectively, 253 miRNAs have been reported with different expression levels in AD patients compared to healthy controls, of which 100 miRNAs are upregulated, 115 miRNAs are downregulated, and 38 miRNAs are both up- and downregulated in AD [90]. In another systematic review extracting dysregulated miRNAs in the peripheral blood from patients with AD, the authors have crossreferenced the dysregulated circulating miRNAs against the dysregulated miRNAs in the brain at the Braak stage III and identified 10 miRNAs [147]. Indeed, the list of 10 miRNAs are identical to those shown in Table 3, indicating that dysregulated miRNAs in association with both early-stage AD pathology and OS regulation can be detected in the peripheral blood. Four of these 10 miRNAs, namely, miR-107, miR-125b, miR-146a, and miR-34a, are found to be altered in the CSF in the same direction as observed in the brain [148, 149]. However, three miRNAs of the 10 miRNAs, namely, miR-125b, miR-146a, and miR-26b, are differentially dysregulated between the brain and blood: upregulated in the brain but downregulated in the peripheral blood. This is probably due to the timing of sampling, since several miRNAs can be inversely dysregulated between early and late stage of AD. For example, miR-146a in the brain and CSF is upregulated at the Braak stage III of prodromal AD but downregulated at the Braak stage VI of advanced AD [94].

4.1.3. Diagnostic Potential of Circulating miRNAs in AD. Of particular note, among the miRNAs shown in Table 3, plasma miR-107 and serum miR-125b measured with a real-time quantitative reverse transcriptase polymerase chain reaction (qRT–PCR) method has been found to show considerably high sensitivity (0.90 for miR-107 and 0.81 for miR-125b) and specificity (0.78 for miR-107 and 0.68 for miR-125b) as a biomarker of AD [149, 150]. Furthermore, decrease in plasma miR-107 is more prominent in amnestic MCI (aMCI) than in AD. Therefore, plasma miR-107 shows even higher sensitivity of 0.98 and specificity of 0.83 to discriminate between patients with aMCI and healthy controls, suggesting a potential role of the circulating miRNA as a diagnostic biomarker at the prodromal stage of AD [149]. Also, serum miR-34c is significantly increased in patients with aMCI and might be a predictive biomarker for diagnosis of aMCI [109].

4.2. MiRNAs as a Therapeutic Target of AD

4.2.1. Recent Advances in RNA-Based Therapeutics. RNA-based therapeutics, such as small interfering RNAs (siRNAs), miRNAs, antisense oligonucleotides (ASOs), aptamers, synthetic miRNAs, and CRISPR-Cas9, have great potential to target currently undruggable genes and gene products and to generate new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to AD [151]. Indeed, patisiran and givosiran are the U.S. Food and Drug Administration (FDA) approved, the first and second RNA interference (RNAi-) based drugs indicated for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and acute hepatic porphyria (AHP), respectively [152, 153]. According to the recent systematic review, 28 ongoing studies are found to be related to the application of RNAs in the treatment and diagnosis of AD, i.e., ASOs (8 targets), miRNA mimics (agomirs) (7 targets), anti-miRNAs (antagomirs) (6 targets), siRNAs (5 targets), and miRNAs (2 targets) [154].

4.2.2. Agomirs and Antagomirs as Therapeutics for AD. The field of miRNAs as therapeutics for AD has attracted attention and potentially offers a variety of solutions including Aβ or tau reduction, enhancement of neuronal survival, inhibition of apoptosis, and protection of synapses [155]. The therapeutic modulation of miRNAs can be done in two ways. The levels of downregulated or upregulated miRNAs can be reversed using agomirs or antagomirs which are antisense
molecules that act to bind and thus inactivate the target miRNA sequence, respectively [156]. Specifically, an intraventricular infusion of miR-107 mimic (agomir) reverses the impairments of spatial memory and long-term potentiation and loss of pyramidal neurons caused by Aβ neurotoxicity in a mouse model of AD via the intraventricular injection of Aβ42 [157]. Conversely, the intrahippocampal delivery of a microRNA-146a specific inhibitor (antagomir) into transgenic mice with five familial AD mutations (5xFAD mice) showed enhanced hippocampal levels of rho-associated, coiled-coil containing protein kinase 1 (ROCK1) protein and repressed tau hyperphosphorylation, partly restoring the memory function in the 5xFAD mice [102]. Similarly, administration of miR-34c antagomir by the third ventricle injection or intranasal delivery markedly increased the brain levels of synaptotagmin 1 (SYT1) and ameliorated the cognitive function in SAMP8 mice [109]. Therefore, several OS-associated miRNAs summarized in Table 3 might be not only diagnostic but also therapeutic targets for AD.

5. Conclusion

Neuronal RNA oxidation in vulnerable neuronal populations in AD [54] and PD [158] was reported in 1999. Since then, involvement of RNA oxidation in the disease pathogenesis has been suggested in diverse neuropsychiatric disorders [4, 8] as well as common chronic diseases beyond the central nervous system such as diabetes and heart failure [159]. In 2015, the existence and the biological significance of oxidized miRNAs were demonstrated in cellular and animal models [19]. Cellular consequences of oxidatively altered RNAs have recently been investigated more intensively and rigorously than before, which provides still limited but an increasing amount of information about disrupted cellular functions in translational machinery and noncoding regulatory mechanisms. Indeed, three independent pathways of apoptosis induction have been identified through formations of oxidized mRNA [16], oxidized tRNA [68], and oxidized miRNA [19]. Besides direct oxidation, expression levels of several miRNAs embedded in upstream regulators or downstream targets of OS are altered in AD. It is noteworthy that both direct oxidation of RNAs and oxidative dysregulation of the miRNA expression occur at an early stage of neurodegeneration. Further understanding of the consequences and cellular handling mechanisms of the oxidatively altered RNAs may provide clues to the underlying mechanisms of neurodegenerative diseases and lead to better early intervention strategies.

Additional Points

Since the submission of this article, it has been reported that formation of 8-oxo-guanine in seed region of miR-1 is sufficient to cause cardiac hypertrophy in mice, which provides novel evidence for an epitranscriptional role of oxidized miRNA in phenotypic alteration (H. Seok, H. Lee, S. Lee et al., “Position-specific oxidation of miR-1 encodes cardiac hypertrophy,” Nature, vol. 584, no. 7820, pp. 279-285, 2020).

Conflicts of Interest

Akihiko Nunomura has received lecture fees from Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. and grant support from Eisai Co., Ltd. George Perry has served on the Board of Neurotrope and Neurotez.

Authors’ Contributions

AN and GP conjointly conceptualized the idea for the review. AN performed the literature search, analyzed the cited studies, and wrote the article. GP critically revised the work and made changes and additions to its intellectual content.

Acknowledgments

This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grants-in-Aid for Scientific Research), Grant number 18K07595 to AN.

References

[1] M. P. Mattson, “Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle,” npj Aging and Mechanisms of Disease, vol. 1, no. 1, 2015.
[2] D. M. A. Oliver and P. H. Reddy, “Molecular basis of Alzheimer’s disease: focus on mitochondria,” Journal of Alzheimer’s Disease, vol. 72, Supplement 1, pp. S95–S116, 2019.
[3] A. Nunomura, T. Hofer, P. I. Moreira, R. J. Castellani, M. A. Smith, and G. Perry, “RNA oxidation in Alzheimer disease and related neurodegenerative disorders,” Acta Neuropathologica, vol. 118, no. 1, pp. 151–166, 2009.
[4] A. Nunomura, P. I. Moreira, R. J. Castellani et al., “Oxidative damage to RNA in aging and neurodegenerative disorders,” Neurotoxicity Research, vol. 22, no. 3, pp. 231–248, 2012.
[5] M. J. McManus, M. P. Murphy, and J. L. Franklin, “The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease,” The Journal of Neuroscience, vol. 31, no. 44, pp. 15703–15715, 2011.
[6] T. Kondo, M. Asai, K. Tsukita et al., “Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness,” Cell Stem Cell, vol. 12, no. 4, pp. 487–496, 2013.
[7] J. H. Birnbaum, D. Wanner, A. F. Gietl et al., “Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients,” Stem Cell Research, vol. 27, pp. 121–130, 2018.
[8] A. Nunomura, H. G. Lee, X. Zhu, and G. Perry, “Consequences of RNA oxidation on protein synthesis rate and fidelity: implications for the pathophysiology of neuropsychiatric disorders,” Biochemical Society Transactions, vol. 45, no. 5, pp. 1053–1066, 2017.
[9] C. L. Simms, B. H. Hudson, J. W. Mosior, A. S. Rangwala, and H. S. Zaher, “An active role for the ribosome in determining the fate of oxidized mRNA,” Cell Reports, vol. 9, no. 4, pp. 1256–1264, 2014.
[10] C. L. Simms and H. S. Zaher, "Quality control of chemically damaged RNA," *Cellular and Molecular Life Sciences*, vol. 73, no. 19, pp. 3639–3653, 2016.

[11] M. A. Lovell, S. Soman, and M. A. Bradley, "Oxidatively modified nucleic acids in preclinical Alzheimer’s disease (PCAD) brain," *Mechanisms of Ageing and Development*, vol. 132, no. 8-9, pp. 443–448, 2011.

[12] M. A. Lovell and W. R. Markesbery, "Oxidatively modified RNA in mild cognitive impairment," *Neurobiology of Disease*, vol. 29, no. 2, pp. 169–175, 2008.

[13] A. Nunomura, T. Tamaoki, N. Motohashi et al., "The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons," *Journal of Neuropathology and Experimental Neurology*, vol. 71, no. 3, pp. 233–241, 2012.

[14] M. A. Lovell, S. Xiong, G. Lyubartseva, and W. R. Markesbery, "Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice," *Free Radical Biology & Medicine*, vol. 46, no. 11, pp. 1527–1533, 2009.

[15] S. Porcellotti, F. Fanelli, A. Fracassi et al., "Oxidative stress during the progression of β-amyloid pathology in the neocortex of the Tg2576 mouse model of Alzheimer’s disease," *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 967203, 18 pages, 2015.

[16] T. Ishii, H. Hayakawa, T. Iwaga, T. Sekiguchi, and M. Sekiguchi, "Specific binding of PCBP1 to heavily oxidized RNA to induce cell death," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 115, no. 26, pp. 6715–6720, 2018.

[17] M. J. Millan, "Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review," *Progress in Neurobiology*, vol. 156, pp. 1–68, 2017.

[18] M. L. Idda, R. Munk, K. Abdelmohsen, and M. Gorospe, "Noncoding RNAs in Alzheimer’s disease," *Wiley Interdiscip Rev RNA*, vol. 9, no. 2, p. e1463, 2018.

[19] J. X. Wang, J. Gao, S. L. Ding et al., "Oxidative modification of miR-184 enables it to target Bcl-xL and Bcl-w," *Molecular Cell*, vol. 59, no. 1, pp. 50–61, 2015.

[20] X. Cao, G. Yeo, A. R. Muotri, T. Kuwabara, and F. H. Gage, "Noncoding RNAs in the mammalian central nervous system," *Annual Review of Neuroscience*, vol. 29, no. 1, pp. 77–103, 2006.

[21] M. F. Mehler and J. S. Mattick, "Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease," *Physiological Reviews*, vol. 87, no. 3, pp. 799–823, 2007.

[22] G. Barry and J. S. Mattick, "The role of regulatory RNA in cognitive evolution," *Trends in Cognitive Sciences*, vol. 16, no. 10, pp. 497–503, 2012.

[23] G. Barry, "Integrating the roles of long and small non-coding RNA in brain function and disease," *Molecular Psychiatry*, vol. 19, no. 4, pp. 410–416, 2014.

[24] S. L. Hollins and M. J. Cairns, "MicroRNA: small RNA mediators of the brains genomic response to environmental stress," *Progress in Neurobiology*, vol. 143, pp. 61–81, 2016.

[25] M. S. Leisegang, K. Schröder, and R. P. Brandes, "Redox regulation and noncoding RNAs," *Antioxidants & Redox Signaling*, vol. 29, no. 9, pp. 793–812, 2018.

[26] N. Amakiri, A. Kubosumi, J. Tran, and P. H. Reddy, "Amyloid beta and microRNAs in Alzheimer’s disease," *Frontiers in Neuroscience*, vol. 13, p. 430, 2019.

[27] K. Konovalova, D. Gerasytmchuk, I. Parkkinen, P. Chmielarz, and A. Domanskyi, "Interplay between microRNAs and oxidative stress in neurodegenerative diseases," *International Journal of Molecular Sciences*, vol. 20, no. 23, p. 6055, 2019.

[28] H. Yanagawa, Y. Ogawa, and M. Ueno, "Redox ribonucleosides. Isolation and characterization of 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine from Torula yeast RNA," *The Journal of Biological Chemistry*, vol. 267, pp. 13320–13326, 1992.

[29] Y. Rhee, M. R. Valentine, and J. Termini, "Oxidative base damage in RNA detected by reverse transcriptase," *Nucleic Acids Research*, vol. 23, no. 16, pp. 3275–3282, 1995.

[30] J. Barciszewski, M. Z. Barciszewska, G. Siboska, S. I. Rattan, and B. F. Clark, "Some unusual nucleic acid bases are products of hydroxyl radical oxidation of DNA and RNA," *Molecular Biology Reports*, vol. 26, no. 4, pp. 231–238, 1999.

[31] Z. Shen, W. Wu, and S. L. Hazen, "Activated leukocytes oxidatively damage DNA, RNA, and the nucleotide pool through halide-dependent formation of hydroxy radical," *Biochemistry*, vol. 39, no. 18, pp. 5474–5482, 2000.

[32] T. Hofer, C. Badouard, E. Bajak, J. L. Ravanat, A. Mattsson, and I. A. Cotgreave, "Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA," *Biological Chemistry*, vol. 386, no. 4, pp. 333–337, 2005.

[33] D. Brégoen and A. Sarasin, "Hypothetical role of RNA damage avoidance in preventing human disease," *Mutation Research*, vol. 577, no. 1-2, pp. 293–302, 2005.

[34] Z. Li, J. Wu, and C. DeLeo, "RNA damage and surveillance under oxidative stress," *IUBMB Life*, vol. 58, no. 10, pp. 581–588, 2006.

[35] P. I. Moreira, A. Nunomura, M. Nakamura et al., "Nucleic acid oxidation in Alzheimer disease," *Free Radical Biology & Medicine*, vol. 44, no. 8, pp. 1493–1505, 2008.

[36] X. Shan, H. Tashiro, and C.-I. G. Lin, "The identification and characterization of oxidized RNAs in Alzheimer’s disease," *The Journal of Neuroscience*, vol. 23, no. 12, pp. 4913–4921, 2003.

[37] K. Honda, M. A. Smith, X. Zhu et al., "Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron," *The Journal of Biological Chemistry*, vol. 280, no. 22, pp. 20978–20986, 2005.

[38] Q. Ding, W. R. Markesbery, Q. Chen, F. Li, and J. N. Keller, "Ribosomal dysfunction is an early event in Alzheimer’s disease," *The Journal of Neuroscience*, vol. 25, no. 40, pp. 9171–9175, 2005.

[39] D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," *Cell*, vol. 116, no. 2, pp. 281–297, 2004.

[40] T. Kawamata, H. Seitz, and Y. Tomari, "Structural determinants of miRNAs for RISC loading and slicer-independent unwinding," *Nature Structural & Molecular Biology*, vol. 16, no. 9, pp. 953–960, 2009.

[41] A. K. L. Leung, "The whereabouts of microRNA actions: cytoplasm and beyond," *Trends in Cell Biology*, vol. 25, no. 10, pp. 601–610, 2015.

[42] B. J. Goldie, C. Fitzsimmons, J. Weidenhofer, J. R. Atkins, D. O. Wang, and M. J. Cairns, "miRNA enriched in human neuroblast nuclei bind the MAZ transcription factor and..."
their precursors contain the MAZ consensus motif,” Frontiers in Molecular Neuroscience, vol. 10, p. 259, 2017.

[43] Z. Zhang, Y. W. Qin, G. Brewer, and Q. Jing, “MicroRNA degradation and turnover: regulating the regulators,” Wiley Interdisciplinary Reviews: RNA, vol. 3, no. 4, pp. 593–600, 2012.

[44] M. Prendecki, J. Florczak-Wyspianska, M. Kowalska et al., “APOE variant alleles and apoE, miR-107 and miR-650 levels in Alzheimer’s disease,” Folia Neuropathologica, vol. 57, no. 2, pp. 106–116, 2019.

[45] M. Essack, A. Salhi, C. Van Neste et al., “DES-ROD: exploring literature to develop new links between RNA oxidation and human diseases,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 5904315, 13 pages, 2020.

[46] B. Zhang, D. Han, Y. Korostelev et al., “Changes in snoRNA and snRNA abundance in the human, chimpanzee, macaque, and mouse brain,” Genome Biology and Evolution, vol. 8, pp. 840–850, 2016.

[47] C. Yao and B. Yu, “Role of long noncoding RNAs and circular RNAs in nerve regeneration,” Frontiers in Molecular Neuroscience, vol. 12, p. 165, 2019.

[48] J. N. Cobley, M. L. Fiorello, and D. M. Bailey, “13 reasons why the brain is susceptible to oxidative stress,” Redox Biology, vol. 15, pp. 490–503, 2018.

[49] J. T. Coyle and P. Puttifarcken, “Oxidative stress, glutamate, and neurodegenerative disorders,” Science, vol. 262, no. 5134, pp. 689–695, 1993.

[50] M. P. Mattson, S. L. Chan, and W. Duan, “Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior,” Physiological Reviews, vol. 82, no. 3, pp. 637–672, 2002.

[51] B. Halliwell, “Reactive oxygen species and the central nervous system,” Journal of Neurochemistry, vol. 59, no. 5, pp. 1609–1623, 1992.

[52] H. Joenje, “Genetic toxicology of oxygen,” Mutation Research, vol. 219, no. 4, pp. 193–208, 1989.

[53] M. A. Takahashi and K. Asada, “Superoxide anion permeability of phospholipid membranes and chloroplast thylakoids,” Archives of Biochemistry and Biophysics, vol. 226, pp. 558–566, 1983.

[54] A. Nunomura, G. Perry, M. A. Pappolla et al., “RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease,” Journal of Neuroscience, vol. 19, no. 6, pp. 1959–1964, 1999.

[55] A. Nunomura, G. Perry, G. Aliev et al., “Oxidative damage is the earliest event in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 8, pp. 759–767, 2001.

[56] J. Schubert and J. W. Wilmer, “Does hydrogen peroxide exist "free" in biological systems?,” Free Radical Biology and Medicine, vol. 11, pp. 545–555, 1991.

[57] K. Hirai, G. Aliev, A. Nunomura et al., “Mitochondrial abnormalities in Alzheimer’s disease,” Journal of Neuroscience, vol. 21, no. 9, pp. 3017–3023, 2001.

[58] M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006.

[59] M. A. Smith, A. Nunomura, X. Zhu, A. Takeda, and G. Perry, “Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease,” Antioxidants & Redox Signaling, vol. 2, no. 3, pp. 413–420, 2000.

[60] F. Taddei, H. Hayakawa, M. Bouton et al., “Counteraction by MutT protein of transcriptional errors caused by oxidative damage,” Science, vol. 278, no. 5355, pp. 128–130, 1997.

[61] T. Ishibashi, H. Hayakawa, R. Ito, M. Miyazawa, Y. Yamagata, and M. Sekiguchi, “Mammalian enzymes for preventing transcriptional errors caused by oxidative damage,” Nucleic Acids Research, vol. 33, no. 12, pp. 3779–3784, 2005.

[62] X. Shan, Y. Chang, and C. L. Glenn Lin, “Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression,” The FASEB Journal, vol. 21, no. 11, pp. 2753–2764, 2007.

[63] A. Calabretta, P. A. Küpfer, and C. J. Leumann, “The effect of RNA base lesions on mRNA translation,” Nucleic Acids Research, vol. 43, no. 9, pp. 4713–4720, 2015.

[64] M. Tanaka, P. B. Chock, and E. R. Stadtman, “Oxidized messenger RNA induces translation errors,” Proceedings of the National Academy of Sciences, vol. 104, no. 1, pp. 66–71, 2007.

[65] A. C. Jacobs, M. J. Resendiz, and M. M. Greenberg, “Direct strand scission from a nucleobase radical in RNA,” Journal of the American Chemical Society, vol. 132, no. 11, pp. 3668–3669, 2010.

[66] Q. Ding, W. R. Markesbery, V. Cecarini, and J. N. Keller, “Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer’s disease,” Neurochemical Research, vol. 31, no. 5, pp. 705–710, 2006.

[67] D. M. Thompson, C. Lu, P. J. Green, and R. Parker, “RNA cleavage is a conserved response to oxidative stress in eukaryotes,” RNA, vol. 14, no. 10, pp. 2095–2103, 2008.

[68] M. Tanaka, P. Jaruga, P. A. Küpfer et al., “RNA oxidation catalyzed by cytochrome c leads to its depurination and cross-linking, which may facilitate cytochrome c release from mitochondria,” Free Radical Biology & Medicine, vol. 53, no. 4, pp. 854–862, 2012.

[69] M. P. Deutscher, “Degradation of RNA in bacteria: comparison of mRNA and stable RNA,” Nucleic Acids Research, vol. 34, no. 2, pp. 659–666, 2006.

[70] P. A. Aas, M. Otterlei, P. O. Falnes et al., “Human and bacterial oxidative demethylyses repair alklylation damage in both RNA and DNA,” Nature, vol. 421, no. 6925, pp. 859–863, 2003.

[71] A. Bellacosa and E. G. Moss, “RNA repair: damage control,” Current Biology, vol. 13, no. 12, pp. R482–R484, 2003.

[72] Z. Li, S. Mall, B. Shin, and J. M. Li, “Battle against RNA oxidation: molecular mechanisms for reducing oxidized RNA to protect cells,” Wiley Interdisciplinary Reviews: RNA, vol. 5, no. 3, pp. 335–346, 2014.

[73] R. Ito, H. Hayakawa, M. Sekiguchi, and T. Ishibashi, “Multiple enzyme activities of Escherichia coli MutT protein for sanitization of DNA and RNA precursor pools,” Biochemistry, vol. 44, no. 17, pp. 6670–6674, 2005.

[74] A. Furuta, T. Iida, Y. Nakabeppu, and T. Iwaki, “Expression of hMTH1 in the hippocampi of control and Alzheimer’s disease,” Neuroreport, vol. 12, no. 13, pp. 2895–2899, 2001.

[75] H. Shimura-Miura, N. Hattori, D. Kang, K. Miyako, Y. Nakabeppu, and Y. Mizuno, “Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson’s disease,” Annals of Neurology, vol. 46, no. 6, pp. 920–924, 1999.
H. Hayakawa, A. Hofer, L. Thelander et al., “Metabolic fate of oxidized guanine ribonucleotides in mammalian cells,” Biochemistry, vol. 38, no. 12, pp. 3610–3614, 1999.

H. Hayakawa, M. Kuwano, and M. Sekiguchi, “Specific binding of 8-oxoguanine-containing RNA to polynucleotide phosphorylase protein,” Biochemistry, vol. 40, no. 33, pp. 9977–9982, 2001.

H. Hayakawa and M. Sekiguchi, “Human polynucleotide phosphorylase protein in response to oxidative stress,” Biochemistry, vol. 45, no. 21, pp. 6749–6755, 2006.

H. Hayakawa, T. Uchiumi, T. Fukuda et al., “Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine,” Biochemistry, vol. 41, no. 42, pp. 12739–12744, 2002.

H. Hayakawa, A. Fujikane, R. Ito, M. Matsumoto, K. I. Nakayama, and M. Sekiguchi, “Human proteins that specifically bind to 8-oxoguanine-containing RNA and their responses to oxidative stress,” Biochemical and Biophysical Research Communications, vol. 403, no. 2, pp. 220–224, 2010.

T. Ishii, H. Hayakawa, T. Sekiguchi, N. Adachi, and M. Sekiguchi, “Role of AuvI in elimination of oxidatively damaged messenger RNA in human cells,” Free Radical Biology & Medicine, vol. 79, pp. 109–116, 2015.

S. Rüegger and H. Großhans, “MicroRNA turnover: when, how, and why,” Trends in Biochemical Sciences, vol. 37, no. 10, pp. 436–446, 2012.

L. L. Yan and H. S. Zaher, “How do cells cope with RNA damage and its consequences?,” The Journal of Biological Chemistry, vol. 294, no. 41, pp. 15158–15171, 2019.

T. Hofer, L. Fontana, S. D. Anton et al., “Long-term effects of caloric restriction or exercise on DNA and RNA oxidation levels in white blood cells and urine in humans,” Rejuvenation Research, vol. 11, no. 4, pp. 793–799, 2008.

J. Liu, E. Head, A. M. Gharib et al., “Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid,” Oxidative Medicine and Cellular Longevity, vol. 14, 2018.

Y. Chang, Q. Kong, X. Shan et al., “Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS,” PLoS One, vol. 3, no. 8, article e2849, 2008.

G. De Luca, I. Ventura, V. Sanghez et al., “Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1,” Aging Cell, vol. 12, no. 4, pp. 695–705, 2013.

M. M. J. van den Berg, J. Krauskopf, J. G. Ramaekers, J. C. S. Kleinjans, J. Prickaerts, and J. J. Briedé, “Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders,” Progress in Neurobiology, vol. 185, p. 101732, 2020.

C. A. Juźwik, S. Drake, Y. Zhang et al., “microRNA dysregulation in neurodegenerative diseases: A systematic review,” Progress in Neurobiology, vol. 182, article 101664, 2019.

W. X. Wang, B. W. Rajeev, A. J. Stromberg et al., “The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of -Site Amyloid Precursor Protein-Cleaving Enzyme I,” The Journal of Neuroscience, vol. 28, no. 5, pp. 1213–1223, 2008.

J. P. Cogswell, J. Ward, I. A. Taylor et al., “Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways,” Journal of Alzheimer’s Disease, vol. 14, no. 1, pp. 27–41, 2008.

M. Müller, H. B. Kuiperij, J. A. Claassen, B. Küsters, and M. M. Verbeek, “MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid,” Neurobiology of Aging, vol. 35, no. 1, pp. 152–158, 2014.

S. Absalon, D. M. Kochanek, V. Raghavan, and A. M. Krichevsky, “MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons,” The Journal of Neuroscience, vol. 33, no. 37, pp. 14645–14659, 2013.

P. Lau, K. Bossers, R. Jankyl et al., “Alteration of the microRNA network during the progression of Alzheimer’s disease,” EMBO Molecular Medicine, vol. 5, no. 10, pp. 1613–1634, 2013.

P. T. Nelson, H. Braak, and W. R. Markesbery, “Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 1, pp. 1–14, 2009.

W. R. Markesbery, “Neuropathologic alterations in mild cognitive impairment: a review,” Journal of Alzheimer’s Disease, vol. 19, no. 1, pp. 221–228, 2010.

Y. Jin, Q. Tu, and M. Liu, “MicroRNA-125b regulates Alzheimer’s disease through SphK1 regulation,” Molecular Medicine Reports, vol. 18, pp. 2373–2380, 2018.

L. Zhang, H. Dong, Y. Si et al., “miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression,” Neurobiology of Aging, vol. 73, pp. 41–49, 2019.

W. J. Lukiw, Y. Zhao, and J. G. Cui, “An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells,” The Journal of Biological Chemistry, vol. 283, pp. 31315–31322, 2008.

G. Wang, Y. Huang, L. L. Wang et al., “MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease,” Scientific Reports, vol. 6, no. 1, article 26697, 2016.

G. Ji, K. Lv, H. Chen et al., “MiR-146a regulates SOD2 expression in H2O2 stimulated PC12 cells,” PLoS One, vol. 8, no. 7, article e69351, 2013.

S. Sarkar, S. Jun, S. Rellick, D. D. Quintana, J. Z. Cavendish, and J. W. Simpkins, “Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity,” Brain Research, vol. 1646, pp. 139–151, 2016.

N. Tong, R. Jin, Z. Zhou, and X. Wu, “Involvement of microRNA-34a in age-related susceptibility to oxidative stress in ARPE-19 cells by targeting the silent mating type information regulation 2 homolog 1/p66shc pathway: implications for...
age-related macular degeneration,” *Frontiers in Aging Neuroscience*, vol. 11, p. 137, 2019.

[106] S. Sarkar, E. B. Engler-Chiurazzi, J. Z. Cavendish et al., “Over-expression of miR-34a induces rapid cognitive impairment and Alzheimer’s disease-like pathology,” *Brain Research*, vol. 1721, p. 146327, 2019.

[107] Y. Zhao, V. Jaber, and W. J. Lukiw, “Over-expressed pathogenic miRNAs in Alzheimer’s disease (AD) and prion disease (PrD) drive deficits in TREM2-mediated Aβ42 peptide clearance,” *Frontiers in Aging Neuroscience*, vol. 8, p. 140, 2016.

[108] X. Wang, P. Liu, H. Zhu et al., “miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation,” *Brain Research Bulletin*, vol. 80, no. 4–5, pp. 268–273, 2009.

[109] Z. Shi, K. Zhang, H. Zhou et al., “Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer’s disease,” *Aging Cell*, vol. 19, no. 3, article e13125, 2020.

[110] Y. Cheng, M. Zhou, and W. Zhou, “MicroRNA-30e regulates TGF-β-mediated NADPH oxidase 4-dependent oxidative stress by Snail1 in atherosclerosis,” *International Journal of Molecular Medicine*, vol. 43, pp. 1806–1816, 2019.

[111] Q. Wu, X. Ye, Y. Xiong et al., “The protective role of microRNA-200c in Alzheimer’s disease pathologies is induced by beta amyloid-triggered endoplasmic reticulum stress,” *Frontiers in Molecular Neuroscience*, vol. 9, p. 140, 2016.

[112] S. Xu, R. Zhang, J. Niu et al., “Oxidative stress mediated-alterations of the microRNA expression profile in mouse hippocampal neurons,” *International Journal of Molecular Sciences*, vol. 13, no. 12, pp. 16945–16960, 2012.

[113] S. Higaki, M. Muramatsu, A. Matsuda et al., “Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer’s disease models,” *PLoS One*, vol. 13, no. 5, article e0196929, 2018.

[114] Y. Du, X. Chi, and W. An, “Downregulation of microRNA-200c-3p reduces damage of hippocampal neurons in epileptic rats by upregulating expression of RECK and inactivating the AKT signaling pathway,” *Chemico-Biological Interactions*, vol. 207, pp. 223–233, 2019.

[115] Y. Jiao, L. Kong, Y. Yao et al., “Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer’s disease,” *Neuropharmacology*, vol. 108, pp. 332–344, 2016.

[116] J. J. Li, G. Dolios, R. Wang, and F. F. Liao, “Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal miRNA expression,” *PLoS One*, vol. 9, no. 3, article e90774, 2014.

[117] D. A. Butterfield, A. M. Swomley, and R. Sultana, “Amyloidβ-Peptide (1–42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression,” *Antioxidants & Redox Signaling*, vol. 19, no. 8, pp. 823–835, 2013.

[118] M. A. Faghihi, M. Zhang, J. Huang et al., “Evidence for natural antisense transcript-mediated inhibition of microRNA function,” *Genome Biology*, vol. 11, no. 5, p. R56, 2010.

[119] X. Chen, S. Zhang, P. Shi, Y. Su, D. Zhang, and N. Li, “MiR-485-5p promotes neuron survival through mediating Rac1/Notch2 signaling pathway after cerebral ischemia/reperfusion,” *Current Neurovascular Research*, vol. 17, no. 3, pp. 259–266, 2020.

[120] L. Geng, T. Zhang, W. Liu, and Y. Chen, “Inhibition of miR-128 abates Aβ-mediated cytotoxicity by targeting PPAR-γ via NF-κB inactivation in primary mouse cortical neurons and neuro2a cells,” *Yonsei Medical Journal*, vol. 59, no. 9, pp. 1096–1106, 2018.

[121] X. Zhao, Y. Jin, L. Li et al., “MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1,” *Pharmacological Research*, vol. 146, p. 104276, 2019.

[122] J. Li and H. Wang, “miR-15b reduces amyloid-β accumulation in SH-SYSY cell line through targeting NF-κB signaling and BACE1,” *Bioscience Reports*, vol. 38, 2018.

[123] A. Lang, S. Grether-Beck, M. Singh et al., “MicroRNA-15b regulates mitochondrial ROS production and the senescence-associated secretory phenotype through sirtuin 4/SIRT4,” *Aging*, vol. 8, no. 3, pp. 484–505, 2016.

[124] R. Zhang, Q. Zhang, J. Niu et al., “Screening of microRNAs associated with Alzheimer’s disease using oxidative stress cell model and different strains of senescence accelerated mice,” *Journal of the Neurological Sciences*, vol. 338, no. 1-2, pp. 57–64, 2014.

[125] S. S. Hébert, K. Horrè, L. Nicolai et al., “MicroRNA regulation of Alzheimer’s amyloid precursor protein expression,” *Neurobiology of Disease*, vol. 33, no. 3, pp. 422–428, 2009.

[126] F. Z. Chen, Y. Zhao, and H. Z. Chen, “MicroRNA-98 reduces amyloid β-protein production and improves oxidative stress and mitochondrial dysfunction through the notch signaling pathway via HEY2 in Alzheimer’s disease mice,” *International Journal of Molecular Medicine*, vol. 43, pp. 91–102, 2018.

[127] Y. Zhou, Z. F. Wang, W. Li et al., “Protective effects of microRNA-330 on amyloid β-protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer’s disease by targeting VAV1 via the MAPK signaling pathway,” *Journal of Cellular Biochemistry*, vol. 119, no. 7, pp. 5437–5448, 2018.

[128] L. L. Wang, L. Min, Q. D. Guo et al., “Profiling microRNA from brain by microarray in a transgenic mouse model of Alzheimer’s disease,” *BioMed Research International*, vol. 2017, 8030311 pages, 2017.

[129] J. L. Jankowsky, D. J. Fadale, J. Anderson et al., “Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase,” *Human Molecular Genetics*, vol. 13, no. 2, pp. 159–170, 2004.

[130] Y. Zhao, M. Zhu, Y. Yu et al., “Brain REST/NRFS is not only a silent repressor but also an active protector,” *Molecular Neurobiology*, vol. 54, no. 1, pp. 541–550, 2017.

[131] J. Y. Hwang and R. S. Zukin, “REST, a master transcriptional regulator in neurodegenerative disease,” *Current Opinion in Neurobiology*, vol. 48, pp. 193–200, 2018.

[132] T. Lu, L. Aron, J. Zullo et al., “REST and stress resistance in ageing and Alzheimer’s disease,” *Nature*, vol. 507, no. 7493, pp. 448–454, 2014.

[133] I. A. Qureshi and M. F. Mehler, “Regulation of non-coding RNA networks in the nervous system—what’s the REST of the story?,” *Neuroscience Letters*, vol. 466, no. 2, pp. 73–80, 2009.

[134] T. Y. Hou, Y. Zhou, L. S. Zhu et al., “Correcting abnormalities in miR-124/PTPN1 signaling rescues tau pathology in Alzheimer’s disease,” *Journal of Neurochemistry*, vol. 154, no. 4, pp. 441–457, 2020.

[135] Y. Xue, H. Qian, J. Hu et al., “Sequential regulatory loops as key gatekeepers for neuronal reprogramming in human cells,” *Nature Neuroscience*, vol. 19, no. 6, pp. 807–815, 2016.
[136] M. P. Mattson and A. Cheng, "Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses," Trends in Neurosciences, vol. 29, no. 11, pp. 632–639, 2006.

[137] M. Ristow, "Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits," Nature Medicine, vol. 20, no. 7, pp. 709–711, 2014.

[138] F. A. Taki, X. Pan, and B. Zhang, "Chronic nicotine exposure systemically alters microRNA expression profiles during post-embryonic stages in Caenorhabditis elegans," Journal of Cellular Physiology, vol. 229, pp. 79–89, 2013.

[139] S. Pinto, V. N. Sato, E. A. De-Souza et al., "Enoxacin extends lifespan of C. elegans by inhibiting miR-34-5p and promoting mitohormesis," Redox Biology, vol. 18, pp. 84–92, 2018.

[140] Y. Xu, M. T. Charles, Z. Luo et al., "Preharvest ultraviolet C treatment affected senescence of stored strawberry fruit with a role microRNAs in the activation of the antioxidant system," Journal of Agricultural and Food Chemistry, vol. 66, no. 46, pp. 12188–12197, 2018.

[141] S. T. Lee, K. Chu, K. H. Jung et al., "MicroRNAs induced during ischemic preconditioning," Stroke, vol. 41, no. 8, pp. 1646–1651, 2010.

[142] T. Miyata, S. Takizawa, and C. van Ypersele de Strihou, "Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets," American Journal of Physiology. Cell Physiology, vol. 300, no. 2, pp. C226–C231, 2011.

[143] S. Moncini, M. Lunghi, A. Valmadre et al., "The miR-15/107 family of microRNAs genes regulates CDK5R1/p35 with implications for Alzheimer’s disease pathogenesis," Molecular Neurobiology, vol. 54, no. 6, pp. 4329–4342, 2017.

[144] H. Shi, B. L. Sun, J. Zhang et al., "miR-15b suppression of Bcl-2 contributes to cerebral ischemic injury and is reversed by sevoflurane preconditioning," CNS Neural Disord Drug Targets, vol. 12, no. 3, pp. 381–391, 2013.

[145] J. Ko, M. A. Hemphill, D. Gabrieli et al., "Smartphone-enabled optofluiddic exosome diagnostic for concussion recovery," Scientific Reports, vol. 6, no. 1, p. 31215, 2016.

[146] B. Xu, Y. Zhang, X.-F. Du et al., "Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity," Cell Research, vol. 27, no. 7, pp. 882–897, 2017.

[147] S. Swarbrick, N. Wragg, S. Ghosh, and A. Stolzing, "Systematic review of miRNA as biomarkers in Alzheimer’s disease," Molecular Neurobiology, vol. 56, no. 9, pp. 6156–6167, 2019.

[148] P. N. Alexandrov, P. Dua, J. M. Hill, S. Bhattacharjee, Y. Zhao, and W. J. Lukiw, "microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int.," Journal of Biochemistry and Molecular Biology, vol. 3, pp. 365–373, 2012.

[149] T. Wang, K. Chen, H. Li et al., "The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA expression for clinical diagnosis of amnestic mild cognitive impairment," The Journal of Clinical Psychiatry, vol. 76, no. 2, pp. 135–141, 2015.

[150] L. Tan, J. T. Yu, Q. Y. Liu et al., "Circulating miR-125b as a biomarker of Alzheimer’s disease," Journal of the Neurological Sciences, vol. 336, no. 1–2, pp. 52–56, 2014.

[151] S. Dowdy, "Overcoming cellular barriers for RNA therapeutics," Nature Biotechnology, vol. 35, no. 3, pp. 222–229, 2017.

[152] D. Adams, A. Gonzalez-Duarte, W. D. O’Riordan et al., "Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis," The New England Journal of Medicine, vol. 379, no. 1, pp. 11–21, 2018.

[153] E. Sardh, P. Harper, M. Balwani et al., "Phase 1 trial of an RNA interference therapy for acute intermittent porphyria," The New England Journal of Medicine, vol. 380, no. 6, pp. 549–558, 2019.

[154] M. Ghaffari, N. Sanadgol, and M. Abdollahi, "A systematic review of current progresses in the nucleic acid-based therapies for neurodegeneration with implications for Alzheimer’s disease," Mini Reviews in Medicinal Chemistry, vol. 20, no. 15, pp. 1499–1517, 2020.

[155] F. Angelucci, K. Cechova, M. Valis, K. Kuca, B. Zhang, and J. Hort, "MicroRNAs in Alzheimer’s disease: diagnostic markers or therapeutic agents?," Frontiers in Pharmacology, vol. 10, p. 665, 2019.

[156] B. Martinez and P. V. Peplow, "MicroRNAs in Parkinson’s disease and emerging therapeutic targets," Neural Regeneration Research, vol. 12, no. 12, pp. 1945–1959, 2017.

[157] B. Shu, X. Zhang, G. Du, Q. Fu, and L. Huang, "MicroRNA-107 prevents amyloid-β-induced neurotoxicity and memory impairment in mice," International Journal of Molecular Medicine, vol. 41, pp. 1665–1672, 2017.

[158] J. Zhang, G. Perry, M. A. Smith et al., "Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons," The American Journal of Pathology, vol. 154, no. 5, pp. 1423–1429, 1999.

[159] H. E. Poulsen, E. Specht, K. Broedbaek et al., "RNA modifications by oxidation: a novel disease mechanism?," Free Radical Biology & Medicine, vol. 52, no. 8, pp. 1353–1361, 2012.